Leukemogenesis by RUNX1-EVI1 and afterward stories ～a message to young doctors and researchers～
三谷 絹子
Special Lecture
The Non-Coding RNA revolution in biomedical research
Pier Paolo Pandolfi
ASH Special Lecture
Novel therapies for treating ITP
Charles Abrams
EHA Special Lecture
The myeloproliferative neoplasms - JAK/STAT signalling and stem cell subversion
Tony Green
JSH学会賞受賞講演
造血幹細胞の特性とその疾患に関する研究
金倉 譲
Presidential Symposium
Dysregulation of RNA in hematological malignancies
Runx1 deficiency decreases ribosome biogenesis and confers stress resistance to hematopoietic stem and progenitor cells
Nancy A. Speck
Epigenetic regulation by noncoding RNA
Daniel G. Tenen
Understanding and targeting spliceosomal gene mutations in cancer
Omar Abdel-Wahab
A novel genetic mechanism of evading anti-tumor immunity in multiple human cancers
小川 誠司
JSH-ASH Joint Symposium（Symposium 8）
Molecular heterogeneity and target therapies of malignant lymphoma in new WHO classification era
Pathology side: A focused update of the revised WHO classification of lymphoid neoplasms
Elaine S. Jaffe
Genetic heterogeneity of DLBCL
加留部 謙之輔
Progress in the management of ATL
石塚 賢治
Clinical side: New target therapies for malignant lymphoma based on molecular heterogeneity
Jonathan W. Friedberg
JSH-EHA Joint Symposium （Symposium 4）
AML with recurrent genetic abnormality in WHO2016
Current treatment of acute promyelocytic leukemia
Miguel A. Sanz
Pediatric AML with genetic alterations
嶋田 明
KIT inhibition in core-binding factor
Peter Paschka
Cooperative mutations in AML with recurrent genetic abnormality
石川 裕一
Asian Joint Panel Discussion
Recent progresses in the treatment of immune thrombocytopenia and coagulopathy in Asia
Clinical diagnosis and genetics of von Willebrand disease
Yeu-Chin Chen
Challenges in diagnosis and treatment of immune thrombocytopenia（ITP）
Ponlapat Rojnuckarin
T cells in the pathogenesis of immune thrombocytopenia
Hou Ming
Current status of ITP in Korea
Soo-Mee Bang
Immune thrombocytopenic purpura: Challenges in management in Indian context
Manoranjan Mahapatra
Management of direct oral anticoagulant - Associated bleeding
Lee Lai Heng
Quick diagnosis for coagulation disorders with prolouged APTT using comprehensive coagulation assays
野上 恵嗣
シンポジウム
Symposium 1
Transcriptional regulation in hematopoiesis and leukemogenesis
A single miRNAs rescue transcriptional factor deficiency in B cell lineage specification though TGF beta pathway
幸谷 愛
The transcription factor IRF8 and enhancer landscape dynamics in the development of mononuclear phagocytes
田村 智彦
Transcriptional and epigenetic dysregulation in pre-leukemic stem cells and their progression to MDS and AML
Ulrich Steidl
Chromosomal rearrangements between 3q21 and 3q26 induce leukemogenesis by misdirecting both EVI1 and GATA2 genes
鈴木 未来子
Mechanistic insights into aberrant chromatin programming in Leukemia
Constanze Bonifer
Symposium 2
Molecular mechanisms of erythropoiesis - Differentiation, iron metabolism, and eryptosis
Transcriptional regulation of erythropoiesis
藤原 亨
Alternative autophagy mediates elimination of mitochondria from embryonic reticulocytes
清水 重臣
Mechanisms and pathophysiological significance of eryptosis
Florian Lang
Identification of erythroferrone and its role in iron metabolism
Tomas Ganz
Symposium 3
Advances in tumor immunology
PD-1 blockade for Hodgkin lymphoma
Stephen M. Ansell
Clinical development of immune checkpoint inhibitors and TR research
北野 滋久
Engineered T cell therapy
Carlos A. Ramos
T-cell receptor repertoire diversity in patients with ATL who receive mogamulizumab
正木 彩子
Oncolytic Coxsackievirus therapy as an immunostimulator
宮本 将平
Symposium 5
Clinical aspects and basic research of MDS: Current situation and future
Pre-leukemic hematopoietic stem cells in human acute myeloid leukemia
Ravi Majeti
Deregulated polycomb function in the pathogenesis of MDS
岩間 厚志
Bone marrow failure in childhood: pathological review of nationwide registry
伊藤 雅文
Novel agents in the treatment of myelodysplastic syndromes
Mikkael A. Sekeres
Leukemia Program, Hematology and Medical Oncology, Cleveland Clinic, USA
Symposium 6
Cutting edge of stem cell transplantations
Donor cell-derived hematological malignancy
加藤 元博
Respiratory virus infections in hematopoietic cell transplant recipients
瀬尾 幸子
Graft-versus-host disease targets granulosa cell of ovarian follicle and causes infertility after allogeneic hematopoietic stem cell transplantation
下地 園子
Gut microbiota and graft-versus-host disease – effects of broad-spectrum antibiotic use on microbiota injury after allogeneic hematopoietic stem cell transplantation
庄野 雄介
Novel cytokine and cellular therapy in transplantation
Geoffrey R. Hill
Symposium 7
血栓止血領域の診療ガイド
成人ITPに対する治療の参照ガイド
冨山 佳昭
TTPならびにaHUSの診療ガイド
和田 英夫
先天性および後天性血友病
日笠 聡
先天性血栓性素因
森下 英理子
静脈血栓塞栓症の診療ガイド
小林 隆夫
Symposium 9
Initial treatment for multiple myeloma: proteasome inhibitor first or immunomodulatory drug first?
First-line treatment incorporating proteasome inhibitor for multiple myeloma
黒田 純也
Clinical trials of IMiD® agents as the first-line therapy of multiple myeloma
Thierry Facon
Clinical trials of proteasome inhibition combined with IMiD in multiple myeloma
Pieter Sonneveld
Combination therapy with monoclonal antibodies for the treatment of newly diagnosed multiple myeloma
西村 倫子
Treatment algorithm of multiple myeloma in Japan
尾崎 修治
Symposium 10
AYA世代の造血器腫瘍の治療の現状と展望
AYA世代のALL: 小児科の立場から
康 勝好
AYA ALLの遺伝子異常と小児型治療による治療戦略
早川 文彦
小児血液・腫瘍医からみたAYA世代のAML
富澤 大輔
AYA世代のAML: 内科の立場から
鍬塚 八千代
AYA世代のリンパ腫: 小児科の立場から
小林 良二
AYA世代のリンパ腫: 内科の立場から
丸山 大
女性医師・研究者シンポジウム
時代を拓く女性医師達
血液がんの起源と進展のメカニズム
坂田（柳元）麻実子
安全な造血幹細胞移植を目指して
瀬尾 幸子
造血細胞移植レジストリと臨床研究
熱田 由子
悪性リンパ腫の発症機序を考える
錦織 桃子
「致死性」と呼ばれた疾患の治癒をめざして
山口 素子
白血病と染色体異常
江口 真理子
プレナリーセッション
Novel leukemia stem cell-targeted therapy for AML based on dual inhibition of EZH1/EZH2
藤田 修平
The transcriptional and alternative splicing landscape of myelodysplastic syndromes
塩澤 裕介
Clinical features and prognosis of unselected patients with AML and RAEB-2: JALSG CS07 study
宮﨑 泰司
The C/EBPβ transcription factor mediates exhaustion of CML stem cells induced by IFNα
横田 明日美
LGR5+ skin stem cells are targeted in GVHD and topical ruxolitinib protects them against GVHD
高橋 秀一郎
New era of platelet biogenesis with a large scale bioreactor optimizing flow and vortex turbulence
中村 壮
教育講演・特別教育講演
教育講演 1 未治療移植適応多発性骨髄腫治療における治療戦略
角南 一貴
教育講演 2 初発移植非適応の多発性骨髄腫における治療戦略
田村 秀人
教育講演 3 再発・難治多発性骨髄腫における治療戦略
佐々木 純
特別教育講演 4 構造に導かれたHIV感染症とAIDSの治療薬の開発 一血液内科医の努力
満屋 裕明
教育講演 5 節外性DLBCLの病態と治療
富田 直人
教育講演 6 成熟T細胞リンパ腫治療の進歩
鈴木 律朗
教育講演 7 悪性リンパ腫のPET/CT ―診断と効果判定のupdate―
寺内 隆司
教育講演 8 Development of novel combination therapy for lymphoma based on preclinical models
